These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 36971507)

  • 21. Safety of treatment with guselkumab in clinical trials for up to 5 years in patients with moderate-to-severe plaque psoriasis.
    Br J Dermatol; 2023 Jul; 189(1):e29. PubMed ID: 37418651
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study.
    Ruiz-Villaverde R; Galan-Gutierrez M; Armario-Hita JC; Rodriguez-Fernandez-Freire L
    Actas Dermosifiliogr; 2024 Mar; 115(3):321-323. PubMed ID: 37923077
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to Kiran Javaid and Cassidy Andruszka: Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies.
    Schäkel K
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e304-e305. PubMed ID: 37950571
    [No Abstract]   [Full Text] [Related]  

  • 24. Author Correction: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
    Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
    Sci Rep; 2024 Mar; 14(1):7144. PubMed ID: 38532006
    [No Abstract]   [Full Text] [Related]  

  • 25. Cold stimulation test in patients with plaque psoriasis.
    Aleksiev T; Ivanova Z; Dobrev H
    Skin Res Technol; 2023 Oct; 29(10):e13421. PubMed ID: 37881047
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.
    Gerdes S; Hoffmann M; Asadullah K; Korge B; Mortazawi D; Krüger N; Personke Y; Tabori S; Gomez M; Wegner S; Kreimendahl F; Taut F; Sticherling M
    J Eur Acad Dermatol Venereol; 2023 Jul; ():. PubMed ID: 37462295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
    Thomas SE; Barenbrug L; Hannink G; Seyger MMB; de Jong EMGJ; van den Reek JMPA
    Drugs; 2024 May; 84(5):565-578. PubMed ID: 38630365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials.
    Potestio L; Martora F; Lauletta G; Vallone Y; Battista T; Megna M
    Clin Cosmet Investig Dermatol; 2024; 17():829-842. PubMed ID: 38616886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series.
    Galluzzo M; Marcelli L; Fico A; Bianchi L; Talamonti M
    Skin Health Dis; 2024 Feb; 4(1):e289. PubMed ID: 38312241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Childhood guttate psoriasis: an updated review.
    Leung AK; Barankin B; Lam JM; Leong KF
    Drugs Context; 2023; 12():. PubMed ID: 37908643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
    Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
    Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
    Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.